Publication | Open Access

A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer

OncologyFolinic Acid ScheduleGastrointestinal OncologyMedicineColorectal CancerMetastatic Colorectal CancerPharmacotherapyCancer TreatmentGramont SchedulePharmacologyRadiation Oncology